Defining the Safety and Efficacy of POSterIor Tibial NeRve StimulatiON in Children

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age5-21
SponsorChi Dang Hornik

About this trial

The purpose of this study is to find out if overactive bladder (OAB) can be safely treated by stimulating a nerve near the ankle. This procedure is called percutaneous tibial nerve stimulation (PTNS). It will be done by a device called the Urgent PC. The Urgent PC works by sending weak electrical signals through a thin needle to the nerve near the ankle. Stimulating this nerve may change bladder control.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 5-21 years old (inclusive)

Obtained legally effective informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization from the participant or the participant's parent/legal guardian/legally authorized representative (LAR)

Minor participant is willing and able to provide assent (as applicable)

History of primary or secondary non-neurogenic OAB as defined by a VDES score of ≥11 and a positive modified bother score within 30 days of consent

Disqualifiers

Known or apparent untreated anatomical abnormality of the lower urinary tract (e.g., untreated ureterocele)

Known neurogenic bladder (e.g., spina bifida, history of spinal cord injury, tethered cord)

Presence of local skin lesions (e.g., rash, skin infections) on the medial surfaces of both ankles at the time of consent

Metal implants in the medial ankle area

Trial design

Design model

Single group

Treatments tested in this trial

  • Urgent PC

    Device

    PTNS is a technique of electrical neuromodulation used primarily for treating OAB. The procedure for PTNS consists of the insertion of a fine needle above the medial malleolus near the posterior tibial nerve followed by the application of low-voltage electrical stimulation that produces sensory and motor responses.

Treatment groups

50 Participants
are divided into 1 treatment group
Group A: Single-Arm CohortExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

The frequency of select safety Events of Special Interest.

1. Electrode site reaction (bruising, bleeding, hematoma, or persistent erythema at the electrode site) 2. Electrode site infection 3. Repeated post-void residual \>60 mL (at ≥ 2 consecutive visits) 4. Urinary tract infection 5. Urinary retention/obstruction 6. Toe numbness 7. Stomach and leg cramps

Time frame
Weekly, Week 1 through Week 16
2

Change in maximum voided volume on the Bladder Diary

The Bladder Diary is a paper diary recommended by the International Children's Continence Society that will be completed by the parent/guardian/LAR or participant. The Bladder Diary includes the following variables: fluid intake, number of voids, volume of voids, degree of urgency, number of incontinent episodes.

Time frame
Week 1, Week 12

Secondary outcomes

1

Proportion of children who experienced complete response, no response, or partial response on the Vancouver Dysfunctional Elimination Survey (VDES)

The VDES is a validated questionnaire that was developed for diagnosing dysfunctional elimination syndrome. The survey uses a five-point Likert scale to score symptoms of bladder dysfunction. Each question is scored on a scale of 0-4, with 0 indicating no complaints and 4 indicating severe symptoms. The total score ranges from 0-52, with higher scores indicating more severe symptoms. The question about voiding frequency is scored differently from the other questions. A neutral choice of five to six urination per day is scored as 0. A urinary frequency of one to two times or more than eight times a day is scored as 4. A urinary frequency of three or four and seven or eight times a day is scored as 2. A cutoff score of 11 is used for patients and 9 for parents to diagnose dysfunctional voiding. The VDES is completed by the parent/legal guardian if participants are \< 9 years old and by participants if they are ≥ 9 years old.

Time frame
Screening, Weekly (Week 1 through Week 12)
2

Change in OAB symptoms (Urgency, Frequency and Daytime Incontinence) reported on the VDES

Change in OAB symptoms will be evaluated from the symptom questions on the VDES survey assessing Urgency, Frequency and Daytime Incontinence. The survey uses a five-point Likert scale to score symptoms of bladder dysfunction. Each question is scored on a scale of 0-4, with 0 indicating no complaints and 4 indicating severe symptoms. The total score ranges from 0-52, with higher scores indicating more severe symptoms. The question about voiding frequency is scored differently from the other questions. A neutral choice of five to six urination per day is scored as 0. A urinary frequency of one to two times or more than eight times a day is scored as 4. A urinary frequency of three or four and seven or eight times a day is scored as 2. A cutoff score of 11 is used for patients and 9 for parents to diagnose dysfunctional voiding. The VDES is completed by the parent/legal guardian if participants are \< 9 years old and by participants if they are ≥ 9 years old.

Time frame
Screening, Weekly (Week 1 through Week 12), Week 16, Week 36
3

Proportion of children who develop a febrile UTI

Febrile UTI occurrence, defined as: • Fever \> 101.5°F (\> 38.6°C); and \>50,000 colony forming units (CFU)/mL of 1 or more speciated organisms; and 10 white blood cells per higher power field (WBC/HPF) on urine microscopy and/or leucocyte esterase \> 2+ on dipstick; and At least 1 of the following symptoms: Gross hematuria (defined as pink or red urine, not a spot of blood on a catheter) OR Abdominal, suprapubic, or flank pain or tenderness OR New or worsening incontinence OR New or worsening urinary urgency, frequency, or hesitancy OR Nausea/vomiting OR Pain with urination OR Malodorous/cloudy urine.

Time frame
Weekly, Week 1 through Week 12
4

The change of Pediatric Incontinence Quality of Life (PINQ) score

The Pediatric Incontinence Quality of Life (PINQ) is a 20-item, self-reported questionnaire that evaluates the QoL of children who have urinary incontinence. Each item is scored on a 5-point Likert scale, with 1 being "no" and 5 being "always". The total score ranges from 20 to 100 points. A higher score indicates a better QoL that is less affected by urinary symptoms. The PINQ is validated for use in children 6-17 years old and has been used in studies of participants up to 30 years old.21,25 The PINQ will be completed by the parent/legal guardian/LAR if participants are \< 9 years old and by participants if they are ≥ 9 years old.

Time frame
Week 1, Week 6, Week 12, Week 16, and Week 36

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Chi Dang Hornik

Lead sponsor

Duke University

Sponsor institution

Duke Clinical Research Institute

Collaborator

The Emmes Company, LLC

Collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Collaborator

This trial is not recruiting at the moment. You can still explore other options: